Skip to content
Taxonomy
Progress in CMT2D Research
Timothy J. Hines, PhD, Postdoctoral Associate at The Jackson Laboratory Read More
A New Treatment for CMT1A
DTx Pharma is directly targeting the genetic cause for CMT1A Read More
CMTA Adds Drug Development Expert Martine Garnier to STAR Advisory Board
The Charcot-Marie-Tooth Association added to its already deep bench of Read More
Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Read More
Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A
Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A GLENOLDEN, Read More
Diana Bharucha-Goebel, MD Joins the CMTA-STAR Advisory Board
In a suite of exciting appointments, the Charcot-Marie-Tooth Association (CMTA) Read More
Data Shows Benefit with PXT3003 in Patients with CMT1A
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit Read More
Orphan Drug Designation for TSHA-120 for Treatment of GAN
Taysha Gene Therapies Receives Orphan Drug Designation from the European Read More
2021 STAR Accomplishments
With our community’s help, the CMTA has invested over $17.5 Read More
Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of Read More
